CD40 and neoplasm: Remarkably, while we observed similar responses between the Panc02 and KPC tumor models, the dose of CD40 agonist used in the Panc02 model (five doses of 12.5 μg) was eight times lower than in the KPC model (first dose 200 μg with four consecutive doses of 100 μg).